BiotechTube

NBI-98854 + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Oct 1, 2014 → Jul 1, 2016

NCT ID
NCT02274558

About NBI-98854 + Placebo

NBI-98854 + Placebo is a phase 3 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02274558. Target conditions include Tardive Dyskinesia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT02679079Phase 2Completed
NCT02581865Phase 2Completed
NCT02274558Phase 3Completed

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
Valbenazine Oral CapsuleNeurocrine BiosciencesApproved
82
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 3
74
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-1065890 + PlaceboNeurocrine BiosciencesPhase 2
49

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82